ImmunityBio (IBRX) reported preliminary Q1 net product revenue Thursday of approximately $44.2 million, which it said would be a 168% increase from a year earlier.

The company said that as of March 31, it had an estimated $380.9 million in cash, cash equivalents, and marketable securities.